All In Biotech

Drug Trial Radar · NCT00595413

Atacicept in Anti-Tumor Necrosis Factor Alpha-naïve Subjects With Rheumatoid Arthritis (AUGUST II)

A Randomised, Double-blind, Placebo Controlled, Multi-centre Phase II Study of Atacicept in Anti-TNFα-naïve Patients With Moderate to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate

Last checked: Nov 20, 2026Latest source record: Feb 17, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 311 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

311

Actual

Start

Sep 2007

Primary completion

Oct 2009

Study completion Oct 2009

Sponsor

Lead sponsor
EMD SeronoIndustry
Sponsor type
Industry
Collaborators
Merck KGaA, Darmstadt, Germany
First posted
Jan 16, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the efficacy of atacicept compared to placebo in the treatment of signs and symptoms in a subject population with active rheumatoid arthritis (RA), inadequate response to methotrexate (MTX) and no previous exposure to anti-tumor necrosis factor alpha (anti-TNFalpha) therapy.

Conditions

  • Rheumatoid Arthritis

Interventions

  • Placebo matched to ataciceptDrug

    Placebo matched to atacicept will be administered subcutaneously twice a week for initial 4 weeks, followed by once a week for subsequent 21 weeks.

  • Atacicept: with loading doseDrug

    Atacicept will be administered subcutaneously at a dose of 150 milligram (mg) twice a week for initial 4 weeks as loading dose, followed by 150 mg once a week for subsequent 21 weeks.

  • AtaciceptDrug

    Atacicept will be administered subcutaneously at a dose of 150 mg once a week for 25 weeks.

  • AdalimumabBiological

    Adalimumab (Humira®) will be administered subcutaneously at a dose of 40 mg every other week for 25 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving American College of Rheumatology 20 Response Based on C-reactive Protein (ACR20-CRP) at Week 26Time frame: Week 26

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Please Contact US Medical Information

    Rockland, Massachusetts

  • Please contact the Merck KGaA Communication Center

    Darmstadt, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.